Panel Discussion: How Can Novel Modalities be Used to Meet the Unmet Needs in CKD?

• Balancing innovation with clinical feasibility and scalable development in kidney disease
• Addressing AAV’s narrow tropism: how do we translate promise into real-world therapies?
• Exploring whether targeted delivery strategies must be disease-specific to maximize impact
• Ensuring RNAi and oligonucleotide therapies achieve durable, clinically meaningful kidney knockdown

Speakers:

Bruce Culleton

Chief Executive Officer

ProKidney

Fredrik Erlandsson

Chief Medical Officer

Purespring Therapeutics

Iva Toudjarska

Founder & Chief Executive Office

Zeal Therapeutics

Yun Joon Jung

Director of Biology

Judo Bio

Pablo Cabral

Executive Director External Innovation

Eli Lilly & Co.